| Drug General Information |
| Drug ID |
D0J6PY
|
| Former ID |
DIB012430
|
| Drug Name |
Taxol/Paraplatin/Herceptin
|
| Synonyms |
Paclitaxel/carboplatin/trastuzumab
|
| Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Phase 3 |
[1]
|
|---|
| Company |
Bristol-Myers Squibb
|
| Target and Pathway |
| Target(s) |
Apoptosis regulator Bcl-2 |
Target Info |
Modulator |
[2]
|
|---|
| Receptor protein-tyrosine kinase erbB-2 |
Target Info |
Inhibitor |
[2]
|
| Human DNA |
Target Info |
Binder |
[1]
|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Focal adhesion
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Prostate cancer
|
|
Small cell lung cancerhsa04012:ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
Adherens junction
|
|
Proteoglycans in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
TSLP Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
Oxidative stress response
|
|
CCKR signaling map STP00012:Cadherin signaling pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
Ceramide signaling pathway
|
|
Direct p53 effectors
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
ATF-2 transcription factor network
|
|
C-MYB transcription factor network
|
|
HIV-1 Nef: Negative effector of Fas and TNF-alpha
|
|
Caspase Cascade in Apoptosis
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Validated targets of C-MYC transcriptional repressionerbb4_pathway:ErbB4 signaling events
|
|
ErbB2/ErbB3 signaling events
|
|
ErbB receptor signaling network
|
|
a6b1 and a6b4 Integrin signaling
|
|
Validated targets of C-MYC transcriptional repression
|
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
|
Reactome
|
Activation of BAD and translocation to mitochondria
|
|
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
|
The NLRP1 inflammasomeR-HSA-1250196:SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
IL-2 Signaling Pathway
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Focal Adhesion
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
Apoptosis
|
|
Nanoparticle triggered autophagic cell death
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Corticotropin-releasing hormone
|
|
Interleukin-11 Signaling Pathway
|
|
Prostate Cancer
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Intrinsic Pathway for Apoptosis
|
|
Apoptosis Modulation and Signaling
|
|
TP53 Network
|
|
Influenza A virus infection
|
|
IL-5 Signaling PathwayWP710:DNA Damage Response (only ATM dependent)
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Bladder Cancer
|
|
Signaling by ERBB2
|
|
Signaling Pathways in Glioblastoma
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
| References |
| REF 1 | Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. |
|---|
| REF 2 | Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. |
|---|
